Skip to content
Trial Eligibility
Menu

Clinical Trials Recruiting near Sacramento, CA

555 clinical trials have a recruiting site within 25 miles of Sacramento, California, according to ClinicalTrials.gov data processed . The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Studies enrolling near Sacramento

Showing 30 studies, nearest first.
  1. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 25 mi
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    17 sites within 25 mi
  3. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 25 mi
  4. Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

    NCT06580314

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    16 sites within 25 mi
  5. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    NCT05174169

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 25 mi
  6. Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

    NCT04871542

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 25 mi
  7. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 25 mi
  8. MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

    NCT03072927

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  9. A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

    NCT04251052

    • Interventional
    • Ages 35 to 50 years
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  10. mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

    NCT05677490

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  11. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  12. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  13. Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

    NCT06998940

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  14. Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

    NCT07198074

    • Phase 3
    • Ages 18 years and older
    • Sex: Female
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 25 mi
  15. Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

    NCT05058651

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  16. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    NCT05675410

    • Phase 3
    • Ages 5 to 60 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  17. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 25 mi
  18. Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    8 sites within 25 mi
  19. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    NCT05561387

    • Phase 3
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 25 mi
  20. Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

    NCT02523014

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  21. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

    NCT02734537

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  22. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  23. Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

    NCT03937635

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  24. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    NCT04267848

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  25. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    NCT04423211

    • Phase 3
    • Ages 18 years and older
    • Sex: Male
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  26. Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

    NCT04566328

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  27. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    NCT05040360

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  28. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    NCT05080673

    • Interventional
    • Ages 45 to 70 years
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  29. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi
  30. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All
    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 25 mi

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.